R ecanalization with tissue plasminogen activator (tPA) or endovascular thrombectomy are the only therapies available for patients with ischemic stroke. 1 Hemorrhagic transformation (HT) is the main complication of thrombolysis; to limit this problem, this drug is used only under restrictive conditions. In addition, HT is an important complication after mechanical thrombectomy, with a similar proportion of appearance. 1 Therefore, research into mechanisms of HT and potential therapies that reduce HT risk and improve prognosis of patients with acute ischemic stroke is greatly needed.
One of the major causes of HT is an increased permeability of the blood-brain barrier (BBB) 2 because of the loss of different components of the microvascular basal lamina, which is related to the increased expression of matrix metalloproteinase 9 (MMP-9) that takes place after ischemia.
3 MMP-9 is upregulated by high-mobility group box 1 via toll-like receptor 4 (TLR4), 4 a receptor implicated in cerebral damage and inflammation elicited by stroke. 5 In humans, serum levels of MMP-9 predict HT in acute stroke 6 and those of high-mobility group box 1 correlate with stroke severity. 7 Now, our aim is to determine whether TLR4 participates in HT development using an in situ thromboembolic stroke model with early or delayed tPA administration.
Materials and Methods
Mice C57BL/10J (TLR4 +/+ ; mice expressing TLR4) and C57BL/10ScNJ (TLR4 −/− , lacking functional TLR4) were subjected to middle cerebral artery occlusion (MCAO) by using an in situ thromboembolic model. Recombinant tPA (10 mg/kg) was administered 20
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Role of TLR4 on Infarct Volume: Effect of Early or Late tPA Administration
In TLR4 +/+ mice, early reperfusion with tPA (20 minutes) after in situ MCAO resulted in smaller infarcts than in control animals (P<0.05 versus TLR4 +/+ ; Figure 1B and 1C), whereas late recanalization (3 hours) did not modify the size of the lesion (P>0.05; Figure 1B and 1C). In these animals, brain TLR4 immunoreactivity was found mainly in neurons ( Figure  I in the online-only Data Supplement).
In TLR4 −/− mice, MCAO produced a significantly smaller infarct volume than in TLR4 +/+ mice (P<0.05; Figure 1B and 1C), corroborating our previous results in a different model. 
Role of TLR4 in tPA-Induced HT
TLR4
+/+ mice showed mild signs of HT and a small bleeding area 24 hours after MCAO. After early reperfusion (20 minutes), both hemorrhage severity and area were similar to the MCAO control group (P>0.05; Figure 2A through 2C), whereas late recanalization (3 hours) by tPA increased the rate of the most severe hemorrhages, hemorrhagic infarction type-1, type-2 and parenchymal hemorrhage (Figure 2A through  2C) . In contrast, in TLR4 −/− mice, late tPA administration did not increase hemorrhage and bleeding area (Figure 2A  through 2C ). Because reduced bleeding could be a consequence of the decreased lesion size, data were normalized by dividing hemorrhage size by infarct size for each animal to avoid this bias. Importantly, after normalization, hemorrhage remained significantly reduced (P<0.05; Figure 2D ).
Role of TLR4 on BBB Damage, MMP-9 Expression, and Leukocyte Infiltration After Late tPA Administration
In TLR4
−/− animals with late reperfusion, extravasated IgG area (indicating BBB damage) was decreased when compared 
with TLR4
+/+ animals (P<0.05, Figure 3A ). In addition, in TLR4 −/− animals, MMP-9 expression after late tPA administration was remarkably reduced when compared with TLR4 +/+ ones (P<0.05; Figure 3B ). MMP-9 expression appeared mainly vascular, as it colocalized with the endothelium marker GLUT-1, but not with neutrophil marker NIMP-R14 ( Figure 3C ). Importantly, there was a linear correlation between MMP-9 and hemorrhage areas, which were mostly coincident ( Figure II in the online-only Data Supplement). We did not find any significant differences in neutrophil infiltration between both groups ( Figure 3D ).
Discussion
Recanalization therapies, either pharmacological or mechanical, are associated with an increased risk of symptomatic HT, a life-threatening complication. In preclinical studies, several compounds have been shown to decrease BBB damage and tPA-induced HT but none of them reduces the risk of HT clinically. Elucidation of mechanisms leading to HT may help to identify therapeutic targets to prevent this sequel. Our results demonstrate that TLR4 is involved in HT induced by delayed tPA administration: the presence of TLR4 (1) increases hemorrhage severity and bleeding area and (2) exacerbates BBB damage and MMP-9 expression after delayed tPA administration. To our knowledge, this study is the first to indicate that TLR4 inhibition can provide protection after ischemic stroke treated with tPA.
HT after delayed tPA infusion is mediated by TLR4, as it was significantly reduced in TLR4-deficient animals, and remained significantly reduced after normalization for infarct size. Although TLR4 implication in cerebral damage and inflammation after stroke is well known, 5 this is the first evidence that demonstrates TLR4 involvement in tPA-induced HT. Supporting our conclusion, TLR4 is upregulated after intracerebral hemorrhage 8 in neurons, as we now describe, astrocytes and microglia.
9 TLR4 signaling pathway contributes to poor outcome after intracerebral hemorrhage in animals and patients. 10 Furthermore, drugs blocking TLR4 suppress intracerebral hemorrhage-induced inflammatory injury. 
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Activation of proteases and infiltration of circulating white cells seem to play an important role in BBB damage and HT, particularly after tPA-induced recanalization. MMP-9 degrades basement membrane components and causes BBB disruption, an effect potentiated by tPA. 11 We previously showed increased MMP-9 immunoreactivity in the ischemic brain of wild-type mice. 5 Likewise, our data now demonstrate MMP-9 expression in animals with delayed tPA reperfusion, where HT is more frequent, supporting MMP-9 as a reliable marker of HT as clinical evidence suggests. 6 Importantly, TLR4-deficient mice present a much lower MMP-9 expression, unlikely due to the smaller infarct size because MMP-9 expression is induced early after ischemia, when infarction has not fully progressed. 4 We also show that MMP-9 immunoreactivity overlaps with the hemorrhagic area, showing a positive correlation. This association is corroborated by our results proving its vascular location. Given the expression pattern found, MMP-9 upregulation in blood vessels could be induced in a paracrine fashion by the activation of neuronal TLR4. Similarly, neuronal TLR4 signaling has been shown to induce brain endothelial activation, 12 which could lead to MMP-9 expression. This does not discard an autocrine mechanism; consistently, it has been demonstrated that high-mobility group box 1 triggers MMP-9 upregulation in neurons and astrocytes predominantly via TLR4 activation after cerebral ischemia. 4 All these data strongly support the TLR4-MMP-9 pathway as a plausible mechanism for tPAinduced HT.
Neutrophil infiltration has been involved in HT 13 but, at least in our model, its importance is diminished by the lack of differences in the groups studied after delayed tPA administration.
Our study presents some limitations: (1) the delayed administration was set at a time still safe in humans, very likely because of species differences; (2) the protective effect of TLR4 absence requires to be studied in future long-term outcome experiments and with behavioral outcomes; and (3) TLR4 involvement in thrombectomy-induced HT remains to be studied.
In conclusion, we report that TLR4 absence decreases HT after delayed tPA administration. Increased MMP-9 expression might be the mechanism underlying this effect. Our data support TLR4 inhibition as a promising therapeutic target to prevent tPA-induced HT and to increase the number of patients that benefit from this therapy.
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